X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-02-07 | ADVM | Scopa James Paul | Dir | P - Purchase | $1.35 | +100,000 | 103,334 | >999% | +$135,000 | ||||||
2024-02-07 | ADVM | Lupher, Jr. Mark L. | Dir | P - Purchase | $1.35 | +130,000 | 130,000 | New | +$175,500 | ||||||
2023-09-15 | ADVM | Seyedkazemi Setareh | Chief Development Officer | S - Sale | $1.52 | -6,201 | 47,674 | -12% | -$9,429 | ||||||
2023-06-07 | ADVM | Rubinstein Linda M | CFO | P - Purchase | $1.45 | +100,000 | 100,000 | New | +$145,490 | ||||||
2023-03-15 | ADVM | Riley Brigit | Chief Scientific Officer | S - Sale | $0.78 | -7,299 | 117,435 | -6% | -$5,705 | ||||||
2023-03-15 | ADVM | Soparkar Peter | COO | S - Sale | $0.78 | -13,360 | 265,891 | -5% | -$10,442 | ||||||
2023-03-15 | ADVM | Fischer Laurent | CEO, Pres, Dir | S - Sale | $0.78 | -41,239 | 692,141 | -6% | -$32,232 | ||||||
2022-09-19 | ADVM | Beckman Richard | Chief Medical Officer | S - Sale | $1.07 | -4,272 | 39,061 | -10% | -$4,570 | ||||||
2022-09-19 | ADVM | Seyedkazemi Setareh | Chief Development Officer | S - Sale | $1.07 | -6,058 | 47,875 | -11% | -$6,480 | ||||||
2022-09-19 | ADVM | Soparkar Peter | See Remarks section | S - Sale | $1.07 | -13,305 | 273,251 | -5% | -$14,232 | ||||||
2022-09-19 | ADVM | Riley Brigit | Chief Scientific Officer | S - Sale | $1.07 | -7,266 | 118,734 | -6% | -$7,772 | ||||||
2022-09-19 | ADVM | Fischer Laurent | CEO, Pres, Dir | S - Sale | $1.07 | -41,082 | 727,380 | -5% | -$43,941 | ||||||
2022-05-23 | ADVM | Seyedkazemi Setareh | Chief Development Officer | P - Purchase | $0.84 | +20,000 | 20,600 | >999% | +$16,800 | ||||||
2022-05-17 | ADVM | Beckman Richard | Chief Medical Officer | P - Purchase | $0.82 | +10,000 | 10,000 | New | +$8,228 | ||||||
2022-05-16 | ADVM | Svoronos Dawn | Dir | P - Purchase | $0.85 | +30,000 | 50,000 | +150% | +$25,578 | ||||||
| M | 2022-05-13 | ADVM | D'Souza Rupert | CFO | P - Purchase | $0.84 | +20,000 | 20,850 | >999% | +$16,857 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |